InvestSMART

Alterity Therapeutics Limited (ASX:ATH)

ALERT: Price-sensitive ASX Announcement for ATH
Current share price for ATH : $0.590 -0.12 (-16.90%)+
Announcement
Release
7 Jul 2026 9:44AM
Price at Release
$0.710
Full Release
download
Summary
Alterity Therapeutics Limited announced that the FDA's official meeting minutes confirmed the registrational pathway for their lead candidate, ATH434, in treating Multiple System Atrophy. The FDA agreed that a single pivotal Phase 3 trial supplemented with confirmatory evidence could support the approval of ATH434. The Phase 3 trial, expected to begin by the end of 2026, will enroll around 200 participants. ATH434, an oral agent aimed at reducing iron accumulation and inhibiting abnormal protein aggregation, has demonstrated positive efficacy and safety in Phase 2 trials and has received Fast Track Designation from the FDA.
Key Points
  • FDA meeting minutes confirm registrational pathway for ATH434 in Multiple System Atrophy (MSA).
  • A single pivotal Phase 3 trial plus confirmatory evidence is sufficient for approval of ATH434.
  • The Phase 3 trial is expected to enroll approximately 200 patients and initiate by year-end 2026.
  • Alterity Therapeutics has received Fast Track Designation for ATH434 from the FDA.
  • ATH434 is designed to reduce iron accumulation and inhibit protein aggregation in neurodegenerative diseases.
  • ATH434 has shown positive results in Phase 2 trials with a favorable safety profile.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.